FDA Criticized Over BPA

Featured Article
Main Category: Regulatory Affairs / Drug Approvals
Also Included In: Nutrition / Diet;  Pediatrics / Children's Health
Article Date: 30 Oct 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:5 stars

5 (1 votes)


The US Food and Drug Administration (FDA) draft assessment on the safety of Bisphenol A, also called BPA, was criticized earlier this week by a panel of experts convened by an advisory subcommittee to the agency. They said the new exposure safety level proposed by the FDA should be at least ten times lower.

BPA is used to make polycarbonate plastics, including those used in plastic baby bottles and drinking water bottles and the lining of metal food packaging. It is one of the highest production volume chemicals in the world. Two million metric tons of BPA were produced in 2003.

Some animal studies suggest there are potential health risks from BPA, especially to infants, and two months ago, a paper in the Journal of the American Medical Association, JAMA suggested there was a link between higher levels of urinary BPA and cardiovascular disease, type 2 diabetes and liver-enzyme abnormalities.

The current controversy is about what level is considered safe for consumers and whether the current safety level set by the FDA is low enough.

The FDA recently produced a draft safety document on BPA which is scheduled to be discussed by an FDA advisory panel (called the Science Board) on 31st October.

In preparation for the Science Board meeting the FDA asked the Board to convene a subcommittee of experts to review the FDA report. The subcommittee comprised two members of the current Science Board and experts drawn from academia and government agencies. They published their conclusions about the FDA draft assessment of BPA earlier this week. They said that: The FDA responded by saying the agency was looking forward to the review of the subcommittee's findings at the Science Board meeting on October 31st and said it agreed that additional research was needed. More research is already planned to address the potential low dose effects of BPA, said the FDA.

The regulatory agencies of the US, Canada, Europe and Japan all agree that "current levels of exposure to BPA through food packaging do not pose an immediate health risk to the general population, including infants and babies", said the FDA, although out of caution, Canada is taking steps to restrict the use of BPA.

In the meantime, parents and carers who wish to use an alternative to polycarbonate plastic for their bottle-fed babies can use glass and other substitutes, or avoid heating formula in polycarbonate bottles, said the FDA.

Click here for the full report from the Science Board Subcommittee (PDF download).

Sources: FDA.

Written by: Catharine Paddock, PhD.


Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our regulatory affairs / drug approvals section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Catharine Paddock, PhD. "FDA Criticized Over BPA." Medical News Today. MediLexicon, Intl., 30 Oct. 2008. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/articles/127426.php>

APA
Catharine Paddock, PhD. (2008, October 30). "FDA Criticized Over BPA." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/articles/127426.php.

Please note: If no author information is provided, the source is cited instead.


Regulatory Affairs / Drug Approvals

Most Popular Articles



Follow Our Regulatory Affairs News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Regulatory Affairs / Drug Approvals Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »